Roy Freeman, MD
Neurology · Boston, MANPI 1518905876
Payments from drug & device makers
Across 271 payments — averaging $4267.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akcea Therapeutics, Inc.$290K
- Biogen$153K
- H. Lundbeck A S$152K
- Regeneron$132K
- Vertex$83K
- GW Pharma Limited$74K
- plus $272K from 20 others
Across 2 payments — averaging $1190.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2K
What the payments were for
- Consulting fees$343,82388%
- Speaking & faculty fees$24,6886%
- Travel & lodging$19,9315%
- Food & beverage$1,8780%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akcea Therapeutics, Inc. | 14 | $289,942 |
| Biogen | 4 | $153,221 |
| H. Lundbeck A S | 34 | $152,483 |
| Regeneron | 101 | $132,120 |
| Vertex | 27 | $83,012 |
| GW Pharma Limited | 22 | $73,686 |
| GW Research Limited | 2 | $52,550 |
| Eli Lilly | 3 | $34,938 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $33,175 |
| GSK | 6 | $30,991 |
| GRT US Holding, Inc. | 6 | $24,454 |
| Lundbeck LLC | 4 | $15,200 |
| Biohaven Pharmaceuticals, Inc. | 13 | $13,992 |
| Orion Corporation | 5 | $12,334 |
| Pfizer | 1 | $11,050 |
| Collegium Pharmaceutical, Inc. | 2 | $8,125 |
| Greenwich Biosciences, Inc. | 1 | $7,270 |
| SK Life Science, Inc. | 1 | $6,000 |
| PTC Therapeutics, Inc. | 7 | $5,010 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $4,047 |
| Astrazeneca UK Limited | 1 | $3,850 |
| Novartis | 1 | $3,341 |
| Novartis Pharma AG | 1 | $2,555 |
| Janssen Global Services, LLC | 1 | $2,480 |
| AbbVie | 1 | $690 |
| Mylan Specialty L.p. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$24,330
- TEGSEDI$6,313
- Cenobamate$6,000
- AIMOVIG$2,555
How this compares
$1,156,595 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Droxidopa | 11 | $4,801 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.